Celcuity (NASDAQ: CELC) — Company Overview, News & Financial Data
Celcuity is a biotechnology company developing novel technologies to personalize cancer treatment and enhance patient outcomes.
Celcuity
Celcuity (NASDAQ:CELC) is a biotechnology company dedicated to revolutionizing the diagnosis and treatment of cancer and other diseases by developing novel cellular analysis technologies. With a strong focus on identifying new therapeutic candidates and advancing precision medicine, Celcuity concentrates on the development of tests that enable the personalization of treatments to improve patient outcomes. Their projects often involve collaborative efforts with leading pharmaceutical companies, aiming to tailor therapies that are more effective and reduce unnecessary exposure to potentially ineffective drugs. Celcuity's primary objective is to bridge the gap between drug development and clinical diagnostics, ensuring patients receive optimal, targeted therapies based on the unique characteristics of their disease.
Snapshot
Operations
Products and/or services of Celcuity
- Development of CELsignia, a functional cellular analysis platform aimed at uncovering patient-specific cancer therapy options.
- Clinical trials for gedatolisib, a targeted therapy for breast cancer patients, in collaboration with leading pharmaceutical companies.
- Investigating the effectiveness of new drug combinations in treating solid tumors, focusing on non-invasive diagnostic solutions.
- Expansion of diagnostic services to include tests for additional cancer types, enhancing personalized treatment plans.
- Partnering with biopharmaceutical firms to utilize CELsignia technology for optimizing drug development processes.
- Advancing research in cellular analysis to identify novel therapeutic targets across various cancer indications.
Celcuity executive team
- Brian F. SullivanCo-Founder, Chairman & CEO
- Lance G. LaingCo-Founder, Chief Science Officer, VP, Secretary & Director
- Vicky HahneChief Financial Officer
- Jodi SieversHead of Investor Relations & Corporate Communications
- Brent EilefsonGeneral Counsel & Chief Compliance Officer
- Sheri SmithActing Head of Clinical Operations
- Igor GorbatchevskyChief Medical Officer
- Eldon C. Mayer IIIChief Commercial Officer
- Byron RobinsonChief Strategy Officer
Latest news about Celcuity
Key financials
Reported results for Celcuity , in USD.
- Market cap
- 3.4B
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -4.3
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 154K | -172.2M | -177M | |
| 0 | -113.3M | -111.8M | |
| 0 | -66.2M | -63.8M | |
| 0 | -39.4M | -40.4M |